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Abstract
Background: In the absence of a validated animal model and/or an immune correlate which predict vaccine-
mediated protection, large-scale clinical trials are currently the only option to prove efficacy of new tuberculosis
candidate vaccines. Tools to facilitate testing of new tuberculosis (TB) vaccines are therefore urgently needed.
Methods: We present here an optimized ex vivo mycobacterial growth inhibition assay (MGIA) using a murine
Mycobacterium tuberculosis infection model. This assay assesses the combined ability of host immune cells to inhibit
mycobacterial growth in response to vaccination. C57BL/6 mice were immunized with Bacillus Calmette-Guérin
(BCG) and growth inhibition of mycobacteria by splenocytes was assessed. Mice were also challenged with
Mycobacterium tuberculosis Erdman, and bacterial burden was assessed in lungs and spleen.
Results: Using the growth inhibition assay, we find a reduction in BCG CFU of 0.3–0.8 log10 after co-culture with
murine splenocytes from BCG vaccinated versus naïve C57BL/6 mice. BCG vaccination in our hands led to a reduction
in bacterial burden after challenge with Mycobacterium tuberculosis of approx. 0.7 log10 CFU in lung and approx. 1
log10 CFU in spleen. This effect was also seen when using Mycobacterium smegmatis as the target of growth inhibition.
An increase in mycobacterial numbers was found when splenocytes from interferon gamma-deficient mice were used,
compared to wild type controls, indicating that immune mechanisms may also be investigated using this assay.
Conclusions: We believe that the ex vivo mycobacterial growth inhibition assay could be a useful tool to help assess
vaccine efficacy in future, alongside other established methods. It could also be a valuable tool for determination of
underlying immune mechanisms.
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Background
Tuberculosis (TB) is a world-wide public health problem
and the biggest cause of death due to a single pathogen.
It is estimated that in 2014, 9.6 million people developed
the disease, and 1.5 million died from it [1]. Bacillus
Calmette-Guérin (BCG) is the only available vaccine. It
confers reliable protection against severe TB in infants
and children, but its efficacy in adults is extremely vari-
able (0–80 %), and a new vaccine is urgently needed to
control the spread of the infection [2, 3]. Progress towards
this goal has been slow. There are several reasons for this
stagnation. Mycobacterium tuberculosis (Mtb) can persist
in infected persons for years without causing disease or
symptoms. Vaccine-mediated protection is therefore diffi-
cult to measure, resulting in a need for lengthy and costly
clinical trials to establish vaccine efficacy. Additionally,
only a handful of new vaccine candidates are currently
under development, and funders have become more reluc-
tant to provide large investments due to a risk of vaccine
failure.
There is currently no validated immune correlate that
predicts efficacy (such as antibody titres used for other in-
fections) and this severely hampers the development and
pre-clinical and clinical testing of TB vaccine candidates.
Additionally, as highlighted by McShane and Williams [4]
we do not have a single validated animal model for the
screening of TB vaccine candidates, although head-to-
head testing of TB vaccine candidates across a range of
animal models can be reasonably used to demonstrate
that vaccines are efficacious. Further, Henao-Tamayo et al.
[5] argue that TB vaccines should be tested against differ-
ent clinical isolates of Mtb, since the BCG Pasteur vaccine
used in their study displayed varying levels of protection
against different Mtb isolates in mouse and guinea pig
models. A novel tool that would allow vaccine screening
in different species may be more time- and cost-efficient
than in vivo challenge experiments and could therefore
help to accelerate vaccine development. The ability to test
several different isolates or lineages of Mtb using cells
from the same animal would reduce the number of ani-
mals needed, and the cost involved in these experiments.
Here, we present an optimized ex vivo mycobacterial
growth inhibition assay (MGIA) for assessment of the sum-
mative vaccine-mediated host capacity to control mycobac-
terial growth. Several variations of mycobacterial growth
inhibition assays have been described previously [6–9]. The
assay described here involves direct co-culture of mouse
splenocytes with mycobacteria, and subsequent measure-
ment of mycobacterial growth inhibition. This particular
variation of the assay has previously been shown to distin-
guish between naïve and immunized individuals in mice as
well as humans by use of PBMC; however, the differences
in mycobacterial burden between those two groups were
small [10, 11]. To allow detection of a range of efficacies
from different vaccine candidates, we aimed to achieve a
difference of >0.5 log10 colony forming units (CFU)
between BCG-naïve and BCG-immunized groups in our
mouse model of TB. Our optimized assay produces a differ-
ence of up to 0.8 log10 CFU in our hands. Growth in-
hibition was also observed when using fast-growing
Mycobacterium smegmatis (Msm) as the target bac-
teria in the MGIA. An in vivo challenge with the Mtb
Erdman laboratory strain resulted in a ~0.7 log10 reduc-
tion in mycobacterial burden in the lungs and a 1 log10
reduction in the spleens of immunized animals, compared
to unimmunized controls. We further demonstrate that
an MGIA can show the importance of non-vaccine medi-
ated interferon gamma (IFNγ)-dependent activity by using
IFNγ-deficient (IFNγ-/-) mice. Collectively, our data sug-
gest that MGIAs could be a promising tool for screening
vaccine candidates pre-clinically, as well as determine the
underlying immune mechanisms.
Methods
Animals
For immunization experiments, female C57BL/6 mice were
acquired from Charles River UK at 5–7 weeks of age. Ani-
mals were acclimatized for at least 5 days before the start of
any experimental procedure. Female B6.129S7-Ifngtm1Ts/J
(IFNγ-/-) and C57BL/6 wild type (WT) controls bred in-
house were used at 10–12 weeks of age. Group sizes of 5–6
mice were used as indicated throughout the manuscript.
Mycobacteria and culture conditions
BCG SSI and BCG Pasteur Aeras strains were obtained
from Aeras (Rockville, MD, USA) as frozen aliquots. These
were stored at -80 °C until needed.M. smegmatis was grown
in 7H9 media with 10 % OADC, 0.5 % Glycerol and 0.05 %
Tween80. At late log phase, bacteria were washed once with
phosphate-buffered saline (PBS) + 0.05 % Tween80, and re-
suspended in PBS + 10 % Glycerol. Aliquots were frozen
and stored at -80 °C until needed.
Immunization
Bacteria were thawed at room temperature and diluted
to a final concentration of 2–5 × 106 CFU/ml in physio-
logical saline solution for irrigation (Baxter Healthcare,
Newbury, UK). Each animal received a subcutaneous in-
jection of 100 μl BCG (immunized groups) or physio-
logical saline solution (control groups) into the left or
right leg flap. Animals were rested for 6 weeks (unless
indicated otherwise) before an ex vivo mycobacterial
growth inhibition assay or infection with M. tuberculosis
was carried out.
Ex vivo Mycobacterial Growth Inhibition Assay (MGIA)
Six weeks after immunization (unless specified other-
wise), spleens were removed aseptically and single cell
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suspensions of splenocytes isolated by mechanical disrup-
tion of spleens through a 100 μm cell strainer. After lysis
of red blood cells, single cell suspensions containing the
desired number of total splenocytes per 300 μl were made
up in antibiotic-free media (RPMI-1640 (Sigma-Aldrich,
Dorset, UK) + 10 % heat-inactivated FBS (Labtech Inter-
national Ltd, Uckfield, UK) + 2 mM L-Glutamine (Fisher
Scientific, Loughborough, UK), and 300 μl aliquots were
added to 2 ml screw cap tubes (Sarstedt, Nümbrecht,
Germany). Mycobacteria were diluted in sufficient volume
for all samples in the same media to a concentration of 90
to 3800 CFU per 300 μl as indicated for individual experi-
ments. 300 μl aliquots of bacteria were added to the sple-
nocytes, and the splenocyte-mycobacteria co-culture was
then incubated on 360° tube rotators (VWR International,
Lutterworth, UK) at 37 °C for 4 days.
After 4 days of incubation, the 2 ml screw cap tubes
were centrifuged at 12,000 rpm in a bench-top microcen-
trifuge. The supernatants were removed (except 100 μl),
and 400 μl of water was added to each tube to lyse host
cells. The tubes were then vortexed briefly three times,
with an incubation at room temperature for 5 min be-
tween each of the vortex steps. Each cell lysate (approx.
500 μl total) was then added to a MGIT tube (BD, Oxford,
UK) and incubated in a BACTEC MGIT liquid culture
system (BD) until registered positive.
To convert time to positivity (TTP) to bacterial num-
bers (CFU), a standard curve was used. To produce the
standard curve, 500 μl of 10-fold dilutions of the myco-
bacterial strains were inoculated into the MGIT tubes,
and TTP was plotted against CFU obtained from plating
aliquots of the mycobacteria on 7H11 agar plates con-
taining 10 % OADC supplement (Yorlab, York, UK) and
0.5 % glycerol. A linear regression analysis was carried
out using GraphPad Prism version 6, and the resulting
equation was used to convert TTP to CFU. Data are pre-
sented here as total number of CFUs per sample, as de-
termined by use of a standard curve (Additional file 1:
Figure S1). The difference between the medians of re-
spective groups is described in the text and figures as Δ
X log, and was calculated by subtracting the median of
the test group (immunized or IFNγ-deficient mice) from
the median of the control group (unimmunized or wild
type mice).
Infection of mice with M. tuberculosis
Female C57BL/6 mice were infected intranasally with M.
tuberculosis Erdman (BEI Resources, Manassas, VA,
USA) 6 weeks after immunization and kept in isolators
under BSL-3 containment. Frozen aliquots as received
from BEI Resources were thawed at room temperature,
and diluted in saline to a concentration of 1.4x104 CFU/
ml. Mice were anaesthetized by an intraperitoneal injec-
tion of a combination of Ketamine (50 mg/kg; Ketalar,
Pfizer Itd, Kent, UK) and Xylazine (10 mg/kg; Rompun;
Berkshire, UK) in saline. Each animal then received
50 μl of the inoculum, estimated to contain 700 CFU.
The number of bacteria in the inoculum was confirmed
by plating aliquots on 7H11 agar plates containing 10 %
OADC and 0.5 % glycerol.
Four weeks after infection, animals were killed by cer-
vical dislocation. Lungs and spleens were removed asep-
tically and homogenized by mechanical disruption in
sterile PBS. A series of 10-fold dilutions of tissue ho-
mogenates in PBS with 0.05 % Tween 80 were plated
onto 7H11 agar plates with 10 % OADC supplement
and 0.5 % glycerol. Plates were incubated at 37 °C and
colonies counted after 3 weeks.
Statistical analysis
Statistical analysis was carried out using GraphPad Prism
software Version 6 (GraphPad, La Jolla, CA, USA). The
specific test used is indicated in each figure legend.
Results
Comparison of BCG SSI and BCG Pasteur in an ex vivo MGIA
As a first step to maximize the difference in bacterial
burden between BCG immunized and control groups in
the MGIA, we investigated growth inhibition using two
different BCG strains, BCG SSI and BCG Pasteur Aeras,
an early passage strain of BCG Pasteur. Groups of 5 and
6 CB57BL/6 mice were immunized with BCG SSI and
BCG Pasteur Aeras, respectively, or given saline as a con-
trol, and an ex vivo MGIA was carried out to assess myco-
bacterial growth inhibition of the same bacterial strains by
host splenocytes at 4 or 6 weeks after immunization (Fig. 1).
1 × 106 cells and three different inocula of BCG were used
for the MGIA as indicated in Fig. 1. The strongest growth
inhibition of BCG SSI was found using 675 CFU. This led
to a reduction of 0.121 log10 CFU in the immunized group
as compared to the control group. No significant differ-
ences were found using 3800 CFU or 90 CFU (Fig. 1a). In
contrast, using 100 CFU BCG Pasteur Aeras lead to a >1
log10 CFU reduction in bacterial numbers in the immu-
nized group (Fig. 1b). Growth inhibition was also observed
with higher inocula of BCG Pasteur Aeras, and although
these were not statistically significant, the differences be-
tween immunized and control groups increased with lower
inocula of BCG. Notably, significantly higher overall bacter-
ial burdens were observed when a higher number of sple-
nocytes (2 × 106) was used (Fig. 1a; 675 CFU, 1 × 106 vs 2 ×
106 splenocytes). This was expected as BCG grows intracel-
lularly in macrophages, and a higher overall number of
splenocytes would provide more host cells for mycobacteria
to grow in; however, we also observed a trend towards a
greater effect on growth inhibition under these conditions
(a reduction of 0.149 log10 CFU vs 0.121 log10 CFU).
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The number of target bacteria and the number of host cells
both influence MGIA outcome
Based on these observations and in order to further im-
prove assay conditions, we proceeded to titrate both the
BCG Pasteur Aeras input inoculum (2000, 500, or
100 CFU) and the number of splenocytes used (1, 3, or
5 × 106; Fig. 2). Data shown in Fig. 1b are included for
comparison. Significant growth inhibition in the immu-
nized versus the control group was observed under several
conditions, ranging from ~0.3 log10 to ~1.2 log10 differ-
ence between medians. Again, we observed more bacterial
growth overall if more splenocytes were present, and we
found that a lower BCG input inoculum and a higher
number of splenocytes generally increased the growth in-
hibition effect in immunized groups. However, lower bac-
terial or splenocyte numbers also increased the variability
within groups (measured as % Coefficient of Variation;
Fig. 2d). We determined minimal conditions for vaccine
candidate testing as delta >0.5 log CFU, CoV < 50 % and
required sample size < 10 per group. These parameters
were met by three of the conditions: 5 × 106 cells +
100 CFU; 5 × 106 cells + 500 CFU; and 3 × 106 cells +
500 CFU (indicated in bold script in Fig. 2d). Taking into
account that the effect size was greatest using 5 × 106 sple-
nocytes + 100 CFU, we determined this as the optimal
condition using BCG Pasteur Aeras and C57BL/6 mice.
Variability and reproducibility between experiments is a
further important consideration. We have repeated the
MGIA under these conditions on four independent occa-
sions (Additional file 2: Figure S2a) and were able to de-
tect significant differences ranging from 0.3–0.8 log10
CFU between immunized and unimmunized groups in
three of those experiments. Pooling of data points from all
experiments leads to a highly significant difference of 0.48
log10 CFU between immunized and control groups
(Additional file 2: Figure S2b).
To assess how our ex vivo assay compares to an in vivo
infection with virulent M. tuberculosis, groups of 6 C57BL/
6 mice were immunized with BCG SSI, BCG Pasteur
Aeras, or saline (control group), rested for 6 weeks, and
then challenged with 700 CFU Mtb Erdman via the intra-
nasal route. Bacterial burden in lungs (Fig. 3a) and spleens
(Fig. 3b) was established 4 weeks after infection. We found
that protection was conferred by both BCG strains, with a
significant reduction of bacterial burden in the lung by
0.73 log10 CFU (BCG SSI) or 0.79 log10 CFU (BCG Pas-
teur Aeras), and in the spleen by 0.93 log10 CFU (BCG
SSI) or 1.06 log10 CFU (BCG Pasteur Aeras), compared to
control animals. There was no significant difference in bac-
terial burden in either lung or spleen between the two
groups immunized with the different BCG strains.
BCG-immunized and control groups can be distinguished in
an MGIA by using fast-growing Mycobacterium smegmatis
In an effort to further optimize the MGIA with regards
to experiment time, the window between immunized
and control groups, and ease of handling, we used the
fast growing, non-pathogenic Mycobacterium smegmatis
as the target bacteria for growth inhibition (Fig. 4). A
difference of 0.7 log10 CFU was achieved between the
two experimental groups (splenocytes from control mice
or from BCG Pasteur Aeras immunized mice), which is
equivalent to using BCG Pasteur Aeras. The overall bac-
terial burden was higher compared to BCG; however,
Fig. 1 Ex vivo MGIA comparing growth inhibition conferred by BCG SSI and BCG Pasteur Aeras. a 1 × 106 splenocytes or 2 × 106 splenocytes from
mice immunized with BCG SSI (grey circles) or given saline (open squares) were co-cultured with 3800, 675, or 90 CFU of BCG SSI. b 1 × 106 splenocytes
from mice immunized with BCG Pasteur Aeras (grey circles) or given saline (open squares) were co-cultured with 2000, 500, or 100 CFU of BCG Pasteur
Aeras. Splenocytes were obtained from a total of 5 immunized and 5 control animals (a) or a total of 6 immunized and 6 control animals (b). Aliquots
from each spleen were cultured with different numbers of mycobacteria as indicated, and are represented by individual data points. Error bars represent
the median +/- interquartile range. Statistical significance was tested using the unpaired t test function in GraphPad Prism
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based on the faster doubling time of Msm, this was ex-
pected. The overall experiment time was reduced by
approx. 7 days.
MGIA reflects non-vaccine mediated, interferon gamma-
dependent responses that are important for control of
mycobacterial growth
To characterize the assay and its potential for use in studies
of immune mechanisms, we used splenocytes from
interferon-gamma (IFNγ)-deficient C57BL/6 mice (IFNγ-/-)
and assessed their ability to control mycobacterial growth
ex vivo in comparison to splenocytes from wild type
C57BL/6 mice. Here, the number of splenocytes (1, 2, or
3 × 106 cells) was titrated against two different BCG Pasteur
Aeras inocula (750 CFU and 100 CFU; Fig. 5). The largest
detectable difference was a 1 log10 increase in CFU in the
IFNγ-/- splenocytes when using 1 × 106 cells and 750 CFU
BCG; using 100 CFU, a 0.8 log10 difference in CFU was ob-
served. This is in concordance with the crucial role of IFNγ
in the control of mycobacterial growth in vivo demon-
strated widely in the literature [12–14]. Interestingly, the dy-
namics in this case are different from the vaccine-induced
growth control described above (Figs. 1, 2, 3 and 4). An in-
crease in the number of splenocytes led to a smaller
difference between the two groups, whilst the opposite
trend was observed when comparing splenocytes from
immunized and unimmunized mice. Similarly, the
higher bacterial inoculum led to overall larger differences
Fig. 2 Optimisation of the ex vivo MGIA using BCG Pasteur Aeras. a 1 × 106, 3 × 106, and 5 × 106 splenocytes (1 M, 3 M, and 5 M, respectively)
from mice immunized with BCG Pasteur Aeras (grey circles) or given saline (open squares) were co-cultured with 2000 CFU (a), 500 CFU (b) or
100 CFU (c) of BCG Pasteur Aeras. Splenocytes were obtained from a total of 6 immunized and 6 control animals. Aliquots from each spleen were
cultured with different numbers of mycobacteria as indicated, and are represented by individual data points. Error bars represent the median +/-
interquartile range. Statistical significance was tested using the unpaired t test function in GraphPad Prism. d Analysis of variation of the data shown in a-c.
*Sample sizes (alpha 0.05, power 0.8) were calculated using the mean values of BCG immunized and naïve groups and using the standard deviation of the
BCG group (standard deviation was greater in the BCG groups than in the saline groups). **Optimal conditions for vaccine candidate testing determined
as delta >0.5 log CFU, CoV < 50 % and required sample size < 10 per group. The analysis was carried out using STATA software
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between the groups, whilst the opposite was the case in
the experiments above.
Discussion
The first step towards optimization of an ex vivo myco-
bacterial growth inhibition assay for pre-clinical vaccine
testing was to compare two different BCG strains, BCG
SSI and BCG Pasteur Aeras (Fig. 1). We found that
using BCG Pasteur Aeras as both the strain for
immunization and the strain for assessment of ex vivo
growth inhibition led to larger differences between im-
munized and control groups (Fig. 1b), compared to
when BCG SSI was used as the MGIA inoculum and
vaccine (Fig. 1a). Importantly, this assay assesses growth
inhibition ex vivo, and thus provides a snapshot of the abil-
ity of the immune system to control mycobacterial growth
at one specific time point. The effect of BCG sub-strains on
the elicited host immune response and conferred protec-
tion has been investigated previously. Irwin and colleagues
find differences after immunization of mice with 3 BCG
sub-strains in the number of IFNγ-producing splenic and
lung T cells [15]. However, this did not translate to differ-
ences in protection from an in vivo infection. Interestingly,
the immune profile changes over time, but these changes
were not translated to in vivo protection [16]. This is in ac-
cordance with our data, as no difference in lung or spleen
bacterial burden was found after Mtb challenge in mice im-
munized with BCG Pasteur Aeras or BCG SSI (Fig. 3). The
MGIA using BCG SSI was carried out 4 weeks after
immunization, whilst the assay using BCG Pasteur Aeras
was carried out 6 weeks after immunization (Fig. 1). It is
possible that a difference in immune responses at different
time points would be apparent in an ex vivo MGIA, which
might contribute towards the differences seen in Fig. 1, but
not after challenge in vivo. We observed a faster growth
rate in vitro of BCG Pasteur Aeras compared to BCG SSI
(data not shown). This could be an additional reason for
the larger differences between control and immunized
groups seen with this strain ex vivo, if faster growth of bac-
teria is found in the control groups with comparable
growth inhibition in the immunized groups. The immune
response to BCG immunization was not characterized here,
Fig. 3 Protection conferred to infection with M. tuberculosis by BCG SSI and BCG Pasteur Aeras. Groups of 6 C57BL/6 mice were infected 6 weeks
after immunization with BCG SSI (grey squares) or BCG Pateur Aeras (grey circles) via the intranasal route with 700 CFUM. tuberculosis Erdman.
Control animals received saline at the time of immunization (open squares). CFUs per organ were determined 4 weeks after infection in lungs
(a) and spleens (b). Each data point represents an individual animal. Error bars represent the median +/- interquartile range. Statistical significance
was determined by one-way ANOVA with Holm-Sidak correction for multiple comparisons using GraphPad Prism
Fig. 4 Ex vivo MGIA using M. smegmatis distinguishes between
immunized and control animals. 5 × 106 splenocytes from mice
immunized with BCG Pasteur Aeras (grey circles) or given saline
(open squares) were co-cultured with 50 CFU of M. smegmatis
5 weeks after immunization. Splenocytes were obtained from 6
immunized and 6 control animals, each represented by an individual
data point. Error bars represent the median +/- interquartile
range. Statistical significance was tested using the unpaired t test
function in GraphPad Prism
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and it is therefore difficult to conclude which factor is the
main driver behind the observed differences. The MGIA
at this stage is not meant to exactly reproduce in vivo ef-
fects, but is a step that provides additional information be-
tween assays determining immunogenicity and in vivo
challenge models. As a better indication of immunization-
mediated growth inhibition was seen using the faster
growing BCG Pasteur Aeras, this strain was used for sub-
sequent experiments.
We reasoned that vaccine-mediated growth inhibition
would depend on the presence of mycobacterial antigen-
specific T cells. As total splenocytes are used in this
assay, the proportion of antigen specific T cells in the
total population is not known, and the total number
may be too low to have an effect on growth inhibition
when using low numbers of splenocytes. Similarly, the
ratio of monocytes to mycobacteria may influence the
outcome as mycobacteria can survive in these cells. In
order to maximize growth inhibition in immunized com-
pared to control splenocytes, we investigated several com-
binations of total host cell numbers (1, 3, or 5 × 106) and
inocula of BCG Pasteur Aeras (2000, 500, or 100 CFU;
Fig. 2). This confirmed that a lower number of bacteria
leads to a greater difference between the groups, regard-
less of the number of host cells. We also observed that a
higher number of host cells increased the difference be-
tween groups. Overall, we determined that 5 × 106 spleno-
cytes and 100 CFU result in a comparatively large and
statistically significant difference between medians of 0.81
log10 CFU whilst variability is acceptable (Coefficient of
Variation = 22.63 % in the BCG group; 8.06 % in the con-
trol group; Fig. 2d). A significant difference was detectable
in three out of four independent experiments, indicating
that some variability remains and that controls of BCG
immunized and naïve animals should be included when
testing experimental TB vaccine candidates (Additional
file 2: Figure S2). Analysis of variance of the data shown in
Fig. 2a-c suggests that sample sizes of 6–8 are required to
achieve statistical power to detect an effect size of >0.5
log10 CFU. Therefore increasing group sizes from the
numbers used here (5–6 per group) may increase overall
reproducibility.
Using fast growing mycobacteria such as M. smegmatis
also led to growth inhibition ex vivo after immunization
with BCG Pasteur Aeras (Fig. 4). The effect size seen
here was similar to the one found when using BCG Pas-
teur Aeras as the target bacteria. We argued that the fas-
ter growth rate of Msm would lead to a shorter study
time, that the non-virulent nature of the bacteria would
ease handling and allow this assay to be carried out in a
wider range of laboratories, and that a faster growth rate
may lead to an accentuation of the effect size of growth
inhibition. The overall experiment time was reduced by
approx. 7 days. However, we did not find more pro-
nounced growth inhibition. This may be because the non-
pathogenic nature of the bacteria does not allow it to grow
proportionately faster intracellularly in cells from non-
immunized mice, or there may not be enough shared anti-
gens between the BCG strain used for immunization and
the target of growth inhibition (Msm).
Importantly, both assays result in inhibition of myco-
bacterial growth by up to 0.7–0.8 log10 CFU. This is
within the range of the reduction of bacterial burden
seen in our own challenge with Mtb Erdman, where we
Fig. 5 Ex vivo MGIA reflects importance of IFNγ for growth control of mycobacteria. 1 × 106, 2 × 106, and 3 × 106 splenocytes from IFNγ-deficient
(filled diamonds) or wild type mice (grey triangles) were co-cultured with 750 CFU (a) or 100 CFU (b) of BCG Pasteur Aeras. Splenocytes were obtained
from a total of 5 IFNγ-deficient and 5 wild type animals. Aliquots from each spleen were cultured with different numbers of mycobacteria as indicated, and
are represented by individual data points. Error bars represent the median +/- interquartile range. Statistical significance was tested using the unpaired t test
function in GraphPad Prism
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found a reduction of approx. 0.7 log10 CFU in lungs and
1 log10 CFU in spleens of immunized animals (Fig. 3).
Others have found varying degrees of reduction in bac-
terial burden depending on the Mtb challenge strain
used (0.75–1.26 log10 CFU in lung, 0.48–1.32 log10
CFU in spleen) [17].
We did not carry out any assessment of ex vivo growth
inhibition using Mtb as the target bacteria, and it is there-
fore uncertain how representative these conditions are of
an infection with virulent Mtb. However, using a growth
inhibition assay that involves co-culture of mycobacteria-
infected bone marrow-derived macrophages with non-
adherent splenocytes from mice vaccinated with different
vaccines, Kolibab and colleagues show that in vitro growth
inhibition of BCG correlates with in vitro growth inhib-
ition of Mtb, as well as with in vivo challenge with Mtb
[18]. We are presenting here a proof-of-concept study to
enable further development of this assay. The advantage
of using BCG as the target bacteria is that no specialized
containment facilities are needed, making the MGIA
much more accessible for a wide range of laboratories.
Using splenocytes from IFNγ-/- mice, we examined
whether the MGIA can be used to assess the impact of im-
mune factors such as IFNγ-dependent activity on growth
control of mycobacteria. We found that splenocytes from
IFNγ-/- mice are more permissive to mycobacterial growth
than their WT counterparts (Fig. 5). This is in accordance
with a wide array of literature describing the crucial role of
IFNγ during tuberculosis [12, 13, 19, 20].
The main factor driving the outcome of the MGIA is
currently unclear. However, given that the ex vivo MGIA
directly assesses the summative ability of the host immune
system to inhibit mycobacterial growth, the vaccine-
mediated immune mechanism that underlies growth con-
trol does not need to be known a priori. In fact, this assay
could help to determine underlying immune mechanisms
of protection by investigating common factors in samples
with efficient growth inhibition. As an ex vivo assay, it is
also easily manipulated, for example by adding or deplet-
ing sub-populations of cells or cytokines. A further
strength lies in the fact that several Mtb strains could be
tested by using one single group of immunized mice and
incubating aliquots of splenocytes with the different Mtb
strains. This would significantly reduce the number of ani-
mals needed in comparison to in vivo challenge experi-
ments, which need one group of animals for each Mtb
strain to be tested – an ethical consideration that is
regarded a priority within the UK research community.
This approach may further allow the comparison of im-
mune mechanisms elicited by the different strains.
Conclusions
We have taken several steps to optimize an existing myco-
bacterial growth inhibition assay in order to provide a
potential tool that could help accelerate TB vaccine devel-
opment. We titrated both host splenocyte numbers and
bacterial inocula, and found three conditions that fulfill our
criteria of delta >0.5 log CFU, Coefficient of Variance <
50 %, and required sample size < 10 per group (Fig. 2d).
Whilst this is an improvement over the previously pub-
lished 0.2 log10 CFU difference [11], variability and repro-
ducibility could be further optimized. However, this assay
could be useful in pre-clinical testing of vaccine candidates,
as an intermediate step between immunogenicity testing
and in vivo challenge experiments. It is both more rapid
and economic than in vivo challenge experiments, and
would also significantly reduce the potential harm experi-
enced by the animals during such experiments. With an
MGIA vaccine candidates could be screened in multiple
doses, with different adjuvant formulations or against dif-
ferent lineages of Mtb before proceeding to in vivo efficacy
testing. One of the strengths of this assay is its potential to
be translated to other species, and therefore the possibility
to test the same vaccine candidate in several animal models
without the need for a pathogenic challenge experiment, or
in humans.
The ex vivo MGIA is an important tool for the TB vac-
cine community and we encourage others to include this
assay into their studies, and to contribute to the
characterization and optimization of parameters will
drive the development of the MGIA forward.
Additional files
Additional file 1: Figure S1. Standard curve of BCG Pasteur Aeras used to
convert TTP to CFU. A linear regression analysis was carried out in GraphPad
Prism. The resulting equation was used to calculate log10 CFU. (PDF 62 kb)
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